This makes Lynparza the first in the PARP inhibitor class of drugs to show efficacy in breast cancer, and the data paves the way for AstraZeneca to file the drug with regulators in this use.

AstraZeneca’s Lynparza has become the first drug in its class approved to treat breast cancer, after the FDA allowed it an expanded licence. The FDA approved Lynparza (olaparib) as a treatment ...

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients. In December ...

Revenues increased across all segments, with sales of most of the key drugs, including Tagrisso, Fasenra, Farxiga, Lynparza and Symbicort, beating estimates. The British drugmaker said that the ...